Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å. Berg J, et al. Among authors: tasken ka. BMC Cancer. 2018 Jul 13;18(1):739. doi: 10.1186/s12885-018-4659-0. BMC Cancer. 2018. PMID: 30005623 Free PMC article.
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X. Nome ME, et al. Among authors: tasken ka. Int J Cancer. 2020 Jan 1;146(1):223-235. doi: 10.1002/ijc.32638. Epub 2019 Oct 8. Int J Cancer. 2020. PMID: 31444972 Free article. Clinical Trial.
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.
Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T. Nyakas M, et al. Among authors: tasken ka. Clin Exp Immunol. 2019 Jul;197(1):74-82. doi: 10.1111/cei.13283. Epub 2019 Mar 21. Clin Exp Immunol. 2019. PMID: 30821848 Free PMC article. Clinical Trial.
PKAI as a potential target for therapeutic intervention.
Taskén K, Hansson V, Aukrust P, Frøland S, Skålhegg BS, Müller F, Tobin D, Vang T, Torgersen KM, Aandahl EM. Taskén K, et al. Drug News Perspect. 2000 Feb;13(1):12-8. Drug News Perspect. 2000. PMID: 12937648
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA. Braadland PR, et al. Among authors: tasken ka. Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479. Oncotarget. 2016. PMID: 26646591 Free PMC article.
PBX3 is a putative biomarker of aggressive prostate cancer.
Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA. Ramberg H, et al. Among authors: tasken ka. Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25. Int J Cancer. 2016. PMID: 27273830 Free article.
139 results